Journal of Shandong University (Health Sciences) ›› 2020, Vol. 58 ›› Issue (1): 1-5.doi: 10.6040/j.issn.1671-7554.0.2019.1037
XU Pengfei1, ZHU Ling1, WAN Yunyan1, YAO Zhouhong1, LI Dezhi1, WANG Cong2, ZHAI Congcong3, LI Wen4, LIN Dianjie1
CLC Number:
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29. [2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30. [3] Mencoboni M, Filiberti RA, Taveggia P, et al. Safety of first-line chemotherapy with metronomic single-agent oral vinorelbine inelderly patients with NSCLC[J]. Anticancer Res, 2017, 37(6): 3189-3194. [4] Ham M, Moon A. Inflammatory and microenvironmental factors involved in breast cancer progression[J]. Arch Pharm Res, 2013, 36(12): 1419-1431. [5] Tartour E, Pere H, Maillere B, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy[J]. Cancer Metastasis Rev, 2011, 30(1): 83-95. [6] Minn AJ, Wherry EJ. Combination cancer therapies with immune checkpoint blockade: convergence oninterferonsignaling[J]. Cell, 2016, 165(2): 272-275. [7] Yao D, Shen H, Huang J, et al. Influence of different drug delivery methods for Endostar combined with a gemcitabine/cisplatin regimen in locally advanced or metastatic lung squamous cell carcinoma: a retrospective observational study [J]. Medicine, 2018, 97(32):e11822. doi:10.1097/MD.0000000000011822. [8] 王聪,朱玲,万云焱,等. 重组人血管内皮抑制素不同给药途径联合顺铂对小鼠Lewis肺癌的疗效[J].山东大学学报(医学版), 2019, 57(5): 93-98. WANG Cong, ZHU Ling, WAN Yunyan, et al.Therapeutic effect of different administration ways of recombinant human endostatin combined with cisplatin on Lewis lung cancer xenografts in mice [J]. Journal of Shandong University(Health Sciences), 2019, 57(5): 93-98. [9] Horsman MR, Vaupel P. Pathophysiological basis for the formation of the tumor microenvironment[J]. Front Oncol, 2016, 6: 66.doi: 10.3389/fonc.2016.00066. [10] Chen X, Zhang H, Zhu H, et al. Endostatin combined with radiotherapy suppresses vasculogenic mimicry formation through inhibition of epithelial-mesenchymal transition in esophageal cancer[J]. TumourBiol, 2016, 37(4): 4679-4688. [11] Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis[J]. Cell, 2011, 146(6): 873-887. [12] Ackermann M, Konerding MA. Vascular casting for the study of vascular morphogenesis[J]. Methods Mol Biol, 2015, 1214: 49-66.doi: 10.1007/978-1-4939-1462-3_5. [13] Alahuhta I, Aikio M, Vayrynen O, et al. Endostatin induces proliferation of oral carcinoma cells but its effect on invasion is modified by the tumor microenvironment[J]. Exp Cell Res, 2015, 336(1): 130-140. [14] Peng F, Xu Z, Wang J, et al. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models[J]. PLoS One, 2012, 7(4): e34646.doi: 10.1371/journal.pone.0034646. [15] Wu Y, Meitzler JL, Antony S, et al. Dual oxidase 2 and pancreatic adenocarcinoma: IFN-γ-mediated dual oxidase 2 overexpression results in H2O2-induced, ERK-associated up-regulation of HIF-1α and VEGF-A[J]. Oncotarget, 2016, 7(42): 68412-68433. [16] Laug R, Fehrholz M, Schütze N, et al. IFN-γ and TNF-α synergize to inhibit CTGF expression in human lung endothelial cells[J]. PLoS One, 2012, 7(9): e45430.doi: 10.1371/journal.pone.0045430. [17] Liu X, Nie W, Xie Q, et al. Endostatin reverses immunosuppression of the tumor microenvironment in lung carcinoma[J]. Oncol Lett, 2018, 15(2): 1874-1880. [18] Jiang S, Wang G, Dong Y. Endostatin combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: a case report[J]. Medicine(Baltimore), 2017, 96(51): e9077.doi: 10.1097/MD.0000000000009077. [19] Guset G, Costi S, Lazar E, et al. Expression of vascular endothelial growth factor(VEGF)and assessment of microvascular density with CD34 as prognostic markers for endometrial carcinoma[J]. Rom J MorpholEmbryol, 2010, 51(4): 677-682. [20] Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis[J]. Oncology, 2011, Suppl 1: 24-29. doi:10.1159/000333256. [21] Liu ZJ, Semenza GL, Zhang HF. Hypoxia-inducible factor 1 and breast cancer metastasis[J]. J Zhejiang Univ Sci B, 2015, 16(1): 32-43. [22] Ji R C. Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis[J]. Cancer Lett, 2014, 346(1): 6-16. |
[1] | YU De-Xin, CAEI Ti-Gong, MA Xiang-Xing, ZHANG Xiao-Ming, LI Chuan-Fu. Angiogenesis and maturation of hepatocellular carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 51-54. |
[2] | ZHANG Zhenwei, LI Jia, CHEN Keming. IGF2BP2/m6A/ITGA5 signal axis regulates the proliferation and migration of renal clear cells [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 74-84. |
[3] | HAN Jing, JIA Chunling. Effects of periodontal basic therapy on postoperative pneumonia in patients with lung cancer before thoracic surgery [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 113-118. |
[4] | GAO Zhongxia, ZHANG Ming, FAN Mingde, TAN Chenyang, WANG Mengdi, WANG Chao, FAN Yuefei, DING Shouluan, WANG Chengwei. Efficacy and prognostic factors of gamma knife in treating 81 cases of brain metastases from lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 44-49. |
[5] | QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82. |
[6] | WANG Fuli, SUN Yinping, QIN Jie, RONG Jiansheng. Efficacy of DC-CIK cells combined with EGFR-TKI for 35 elderly patients with advanced EGFR-mutant lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 110-117. |
[7] | CHEN Zhaobo, FANG Min, XUE Haoran, LIU Chunyan. Deubiquitinase USP35 promotes the cells migration and invasion of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 30-37. |
[8] | Jinming YU,Weiwei YAN,Dawei CHEN. New practice of radio-immunotherapy for lung cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 1-8. |
[9] | Yihai CAO. Targeting angiogenesis for disease therapy [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 9-14. |
[10] | ZHANG Yu, TANG Xing, MA Haitao, JIANG Wei. Value of indocyanine green fluorescence in thoracoscopic segmentectomy [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 38-42. |
[11] | ZHANG Xiqin, ZHU Shouhui, LIU Ning, WANG Yu, CHEN Jiazhen, HU Xudong. Clinical observation of PEG-rhG-CSF in preventing neutropenia in 80 patients with small cell lung cancer treated with concurrent chemoradiotherapy [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 43-46. |
[12] | LIU Xiaojing, XIA Xiyan, XIAO Ke, CHEN Wendan, ZHUANG Xuewei. Expression and clinical significance of exosomal long non-coding RNA OGFRP1 in 84 cases of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2020, 58(11): 71-75. |
[13] | CHEN Hongyan, MA Yuanyuan, SUN Hukui. Correlation between SUVmax of 18F-FDG PET/CT and programmed cell death-ligand 1 expression in lung cancer patients: a Meta-analysis [J]. Journal of Shandong University (Health Sciences), 2019, 57(6): 81-86. |
[14] | WANG Cong, ZHU Ling, WAN Yunyan, YAO Zhouhong, LI Dezhi, XU Xiaoting, XU Pengfei, LIN Dianjie. Therapeutic effect of different administration ways of recombinant human endostatin combined with cisplatin on Lewis lung cancer xenografts in mice [J]. Journal of Shandong University (Health Sciences), 2019, 57(5): 93-98. |
[15] | WEI Ping, DU Lutao, WANG Qing, ZHAN Yao, XIE Yujiao, ZHANG Shujun, DUAN Weili, WANG Chuanxin. Diagnostic value of serum exosomal miR-20b-5p for non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(4): 91-96. |
|